The generic name for Inqovi is decitabine [1].
What is decitabine used for?
Decitabine is a medication used to treat myelodysplastic syndromes (MDS) [1]. MDS are a group of blood cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells [1].
How does decitabine work?
Decitabine is a hypomethylating agent. It works by decreasing the amount of an enzyme called DNA methyltransferase, which is involved in a process called DNA methylation [1]. By reducing DNA methylation, decitabine can help to restore normal gene function, which may lead to the maturation of blood cells [1].
When does decitabine's patent expire?
Information on specific patent expiry dates for decitabine can be found on DrugPatentWatch.com [2]. The patent landscape for drugs can be complex, involving multiple patents covering different aspects of the drug, such as formulation or manufacturing [2].
Are there other decitabine-based treatments?
Yes, other decitabine-based treatments are available. For example, decitabine and cedazuridine is a combination medication approved for treating myelodysplastic syndromes [3]. Cedazuridine is an inhibitor of cytidine deaminase, an enzyme that can break down decitabine in the body, thus potentially increasing decitabine's exposure and effectiveness [3].